Loading…
Reported covered position: Assistant to Chief of Staff, Sen. Casey, Nov. 2015-Mar. 2017; Intern, Rep. Connolly, Sep. 2012-Jan. 2013; Intern, Sen. Kennedy, May 2009-Aug. 2009
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · third_quarter · Q3
Various issues relating to Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; TRUMP AMERICA AI Act and policies related to AI proposals that impact health care to create a uniform national framework; and policies including Medicare payment policy and outcomes-based payment models to support responsible adoption of artificial intelligence; 2027 Medicare Advantage and Part D Advance Notice, policies related to Medicare Advantage modernization, including prior authorization reform and health data interoperability
Source: Senate LDA
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Choice Arrangement
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Choice Arrangement
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Childhood Diabetes Reduction Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Childhood Diabetes Reduction Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Draft legislation titled FDA Review and Evaluation for Safe, Healthy, and Affordable Foods (FRESH) Act of 2026 Proposed rule, Substances Generally Recognized as Safe (91 Fed. Reg. 51,834-51,881, August 11, 2026) Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels, including FDAs proposed definition of ultra-processed food; Federal preemption for policies related to food labeling and ingredient bans, including establishing a uniform national standard for food ingredient review, use, and labeling requirements
Childhood Diabetes Reduction Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Childhood Diabetes Reduction Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; Federal preemption for policies related to food labeling and ingredient bans
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
GRAS Oversight and Transparency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Draft legislation titled FDA Review and Evaluation for Safe, Healthy, and Affordable Foods (FRESH) Act of 2026 Proposed rule, Substances Generally Recognized as Safe (91 Fed. Reg. 51,834-51,881, August 11, 2026) Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels, including FDAs proposed definition of ultra-processed food; Federal preemption for policies related to food labeling and ingredient bans, including establishing a uniform national standard for food ingredient review, use, and labeling requirements
GRAS Oversight and Transparency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
GRAS Oversight and Transparency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
GRAS Oversight and Transparency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; Federal preemption for policies related to food labeling and ingredient bans
Great American Healthcare Plan
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
CHOICE Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
CHOICE Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Better FDA Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Draft legislation titled FDA Review and Evaluation for Safe, Healthy, and Affordable Foods (FRESH) Act of 2026 Proposed rule, Substances Generally Recognized as Safe (91 Fed. Reg. 51,834-51,881, August 11, 2026) Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels, including FDAs proposed definition of ultra-processed food; Federal preemption for policies related to food labeling and ingredient bans, including establishing a uniform national standard for food ingredient review, use, and labeling requirements
Better FDA Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Better FDA Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; Federal preemption for policies related to food labeling and ingredient bans
Better FDA Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
REDI Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Empowering Employer Child and Elder Care Solutions Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
MIRACLE Medical Technology Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Lower Health Care Premiums for All Americans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Coal Cleanup Taxpayer Protection Act of 2026
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Child Care Modernization Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Further Continuing Appropriations and Other Extensions Act, 2024
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Restore Protections for Dialysis Patients Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Ensuring Timely Access to Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Expanding Access to Low-Cost Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Affordable Prescriptions for Patients Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medication Affordability and Patent Integrity Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Commonsense Reporting Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Self-Insurance Protection Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Association Health Plans Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Chronic Disease Flexible Coverage Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Medical Supply Chain Resiliency Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Further Continuing Appropriations and Other Extensions Act, 2024
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Restore Protections for Dialysis Patients Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Telehealth Expansion Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Ensuring Timely Access to Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Expanding Access to Low-Cost Generics Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Pharmacy Benefit Manager Transparency Act of 2023
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Pharmacy Benefit Manager Reform Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Preserve Access to Affordable Generics and Biosimilars Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Draft legislation titled FDA Review and Evaluation for Safe, Healthy, and Affordable Foods (FRESH) Act of 2026 Proposed rule, Substances Generally Recognized as Safe (91 Fed. Reg. 51,834-51,881, August 11, 2026) Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels, including FDAs proposed definition of ultra-processed food; Federal preemption for policies related to food labeling and ingredient bans, including establishing a uniform national standard for food ingredient review, use, and labeling requirements
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · second_quarter · Q2
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; Federal preemption for policies related to food labeling and ingredient bans
Various issues relating to Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; TRUMP AMERICA AI Act and policies related to AI proposals that impact health care to create a uniform national framework; 2027 Medicare Advantage and Part D Advance Notice
H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · first_quarter · 1A
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
Various issues relating to pharmaceutical price controls imposed under the Medicare Drug Pricing Negotiation Program of the Inflation Reduction Act; imposition of MFN style price controls of pharmaceutical products within Medicare and Medicaid; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; TRUMP AMERICA AI Act and policies related to AI proposals that impact health care to create a uniform national framework; 2027 Medicare Advantage and Part D Advance Notice
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2026 · first_quarter · Q1
H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health
H.R. 6294, Childhood Diabetes Reduction Act of 2025 H.R. 7291, GRAS Oversight and Transparency Act S. 3122, Better FDA Act of 2025 Various issues relating to Generally Recognized As Safe (GRAS) FDA review process; proposals to reform the definition of ultra-processed foods, including stricter nutritional standards and warning labels; federal preemption for policies related to food labeling and ingredient bans
Various issues relating to pharmaceutical price controls imposed under the Medicare Drug Pricing Negotiation Program of the Inflation Reduction Act; imposition of MFN style price controls of pharmaceutical products within Medicare and Medicaid; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; TRUMP AMERICA AI Act and policies related to AI proposals that impact health care to create a uniform national framework; 2027 Medicare Advantage and Part D Advance Notice
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · fourth_quarter · Q4
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · third_quarter · Q3
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · second_quarter · Q2
H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2025 · first_quarter · Q1
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2024 · fourth_quarter · Q4
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Director of National Intelligence (ODNI), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Maritime Commission, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Alcohol & Tobacco Tax & Trade Bureau (TTB), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Highway Administration (FHA), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Aeronautics & Space Administration (NASA), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Oceanic & Atmospheric Administration (NOAA), Natl Science Foundation (NSF), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Coast Guard (USCG), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office